

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 12-001857- -00007-0000

Fecha: 2014-08-28 15:50:36 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 523 RESPUESTA Folios: 39

Doctor

José Luis Salazar

Director de División de Nuevas Creaciones (C)

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

E. S. D.

Referencia: Expediente No. 12.001.857

Solicitud de Patente de Invención titulada: "Compuestos para la reducción de producción de β -amiloide"

Solicitante: Bristol-Myers Squibb Company

RESPUESTA AL AUTO NOTIFICADO POR FIJACIÓN EN LISTA No. 22**DEL 3 DE JUNIO DE 2014, OFICIO NO. 6319 (EXAMEN DE FONDO)**

ÁLVARO CORREA ORDÓÑEZ, mayor de edad y vecino de Bogotá D.C., identificado tal como aparece al pie de mi firma, en mi carácter de apoderado de la sociedad en referencia, doy respuesta al auto emanado por ese Despacho dentro del término legal:

1. Objeciones del Examinador**1.1 Claridad de la solicitud**

Con relación a la claridad de la solicitud su Despacho en forma resumida manifiesta lo siguiente:

"La reivindicación 1 no es clara porque reclama una estructura química de forma A-B-C-D que representa hipervariabilidad es decir, las posibles definiciones son infinitas. Lo anterior, constituye una falta de unidad a priori.

Por lo que el examinador sugiere restringir la fórmula general (I).

El examinador menciona además que las reivindicaciones 1-4, 6-7, 9-10 y 12-13 no son

claras porque el término "opcionalmente" precediendo una característica es impreciso. El examinador sugiere sustituirlo por un término concreto.

Así mismo, su Despacho sugiere restringir la solicitud a los sustituyentes que han sido probados, es decir, que se encuentran debidamente sustentados de acuerdo a lo presentado en la tabla 1 del Oficio No. 6319.

1.2 Unidad de Invención

Con relación al requisito de unidad de invención su Despacho menciona que la solicitud no cumple con dicho requisito ya que se refiere a dos grupos inventivos:

1. Grupo: Compuestos cuyo núcleo bicíclico presenta un sistema conformado por un primer anillo de pirimidina y un segundo anillo de cinco miembros..
2. Grupo: Compuestos cuyo núcleo bicíclico presenta un sistema conformado por un primer anillo de pirimidina y un segundo anillo de seis miembros.

1.3 Análisis de la oposición



Argumentos de Procaps S.A

La sociedad opositora en resumen argumenta que la presente invención carece del requisito de nivel inventivo debido a las enseñanzas del documento WO2009087127, se establece que dicho documento divulga compuestos útiles en el tratamiento del Alzheimer y otras enfermedades neurológicas caracterizado por un núcleo bicíclico que comprende un sistema de anillos, donde el primer anillo corresponde a la pirimidina unido a un grupo anilino y un segundo anillo que corresponde a un cicloalcano de seis miembros.

Respuesta del solicitante:

El solicitante señala que las enseñanzas expuestas en el documento WO2009087127 no permiten a una persona normalmente versada en la materia alcanzar los compuestos reclamados comoquiera que los compuestos reclamados se diferencian de los compuestos

divulgados en los sustituyentes Rb de la posición 4 del anillo de piridina de acuerdo al siguiente cuadro:

La presente solicitud	WO2009087127
 Ejemplo 189	 WO 2009 087127 Ejemplo 38

Respuesta del examinador:

El examinador afirma que el documento WO2009087127 aporta elementos que sí desvirtúan el nivel inventivo de la presente solicitud.

1.4 Nivel inventivo

Con relación al nivel inventivo su Despacho establece que los documentos WO2009087127 (D1¹)y US20090099195 (D2²) afectan el nivel inventivo de las reivindicaciones 1 a 14 de la solicitud en estudio.

En forma resumida el examinador argumenta:

" Los documentos D1 y D2 se consideran el estado de la técnica cercano a la invención definida en la reivindicación 1 porque en el caso del documento D1 divulga compuestos heteroaromáticos moduladores β-amiloides útiles en el tratamiento de enfermedades degenerativas como el Alzheimer (Resumen). Por su parte, el documento D2 divulga compuestos heteroaromáticos y composiciones que los comprenden, útiles en el tratamiento de enfermedades como el Alzheimer, la ansiedad como también en la terapia del dolor (Resumen y Pag. 5, Parr. 0069).

¹ "Modulators for amyloid Beta"
² "Terapeutic compounds 570"

La diferencia entre el compuesto, definido en la reivindicación 1 y el compuesto divulgado en el documento D1 consiste en que los compuestos reclamados incluyen en la posición 4 del anillo de pirimidina un heterociclo nitrogenado C4-C7 mientras que en la misma posición del anillo de pirimidina los compuestos revelados en el documento D1 incluyen un alquilo C1-C7.

El efecto que logra el incluir en la posición 4 del anillo de pirimidina un sustituyente como un heterociclo nitrogenado C4-C7 consiste en que se mejora su efecto inhibidor β -amiloide. Por lo tanto, el problema técnico objetivo que pretende resolver esta invención se puede formular así: "como proporcionar compuestos alternativos útiles en el tratamiento del Alzheimer?".

Sin embargo, la inclusión dentro de la estructura de compuestos útiles en el tratamiento del Alzheimer de un heterociclo nitrogenado C4-C7 en la posición 4 del anillo de pirimidina, esta divulgado en el documento D2 que enseña compuestos útiles en el tratamiento del Alzheimer que incluyen en la posición 4 del anillo de pirimidina como sustituyente un heterociclo nitrogenado C2-C9 (Resumen, Pag. 5, Parr. 0069 y Pags. 197-198, Rv.1).

En consecuencia, la persona del oficio normalmente versada en la materia, incluiría el heterociclo nitrogenado C2-C9 ubicado en la posición 4 del anillo de pirimidina de acuerdo con lo divulgado en el documento D2 en la posición 4 del anillo de pirimidina de los compuestos revelados en el documento D1, cambiando el alquilo por el heterociclo nitrogenado, para llegar así al objeto de la reivindicación 1 de la solicitud. Por lo cual se considera obvia.

Puesto que las reivindicaciones dependientes 2-14 no mencionan características técnicas esenciales acerca del compuesto reclamado, tampoco se pueden considerar inventivas".

2. Argumentos a favor de la patentabilidad de la solicitud

2.1 Claridad de la solicitud

Modificación a una solicitud en trámite:

Con el objeto de superar las observaciones del examinador y de conformidad con el artículo

34 de la Decisión 486 que permite al solicitante efectuar modificaciones a su solicitud en cualquier momento del trámite sin que se presente ampliación de la invención originalmente presentada, me permito presentar un nuevo pliego reivindicatorio conformado por 8 reivindicaciones.

Dicho capítulo se limitó de tal forma que solo se reclama compuestos que se encuentran debidamente sustentados en la memoria descriptiva originalmente presentada mediante ejemplos. Así mismo se canceló la expresión "opcionalmente".

De esta forma se da por superada la observación en cuanto al requisito de claridad.

2.2 Unidad de invención

Con el objeto de superar la objeción de la unidad de invención, se presenta un nuevo pliego reivindicatorio como sustituto del anteriormente presentado, el cual se limitó a los compuestos donde el núcleo bicíclico está conformado por un primer anillo de pirimidina y un segundo anillo de 5 miembros.

De esta forma se da por superada la objeción de unidad de invención.

2.3 Nivel inventivo

El nivel inventivo de una solicitud se encuentra definido en el Artículo 18 de la Decisión 486 y se establece cuando *"si para una persona del oficio normalmente versada en la materia técnica correspondiente, esa invención no hubiese resultado obvia ni se hubiese derivado de manera evidente del estado de la técnica"*.

Contrario a lo que plantea el Examinador, los documentos del arte previo citados no afectan el nivel inventivo de la presente solicitud por cuanto no es posible derivar la presente invención a partir de las enseñanzas presentadas en los documentos WO2009087127 (D1) y US20090099195 (D2), por las siguientes razones:

Como se informó anteriormente se presenta un nuevo pliego reivindicatorio como sustituto del anteriormente presentado, el cual presenta limitaciones significativas.

En particular el examinador podrá notar que el núcleo bicíclico está conformado por un primer anillo de pirimidina y un segundo anillo de 5 miembros.

Es importante aclarar que la presente invención reclama compuestos que son útiles en la reducción de la producción de β -amiloide, estos compuestos pueden ser útiles en el tratamiento de varias condiciones neurológicas, en particular, la enfermedad de Alzheimer.

Con relación al documento D1 (WO2009087127) que según su Despacho afecta el nivel inventivo de la solicitud en estudio, respetuosamente mi presentada no esta de acuerdo ya que el componente R^5 en dicho documento está limitado a "hidrógeno, alquilo inferior o hidroxilo". Por el contrario, en la presente invención, el componente correspondiente R^b en la estructura del solicitante es $-NR^xR^y$. Por lo tanto, el documento D1 no enseña ni revela el grupo amina importante unido al anillo pirimidina.

Para resolver supuestamente este problema, el examinador cita el documento US 20090099195 (D2) por su enseñanza de un sustituyente amina en el anillo de pirimidina. Sin embargo, a diferencia de la presente invención, los compuestos del documento D2 no se dirigen a la reducción de producción de β -amiloide. Por el contrario, estos compuestos funcionan como antagonistas de los receptores P2X3. Por lo tanto, estos funcionan de una manera completamente diferente a los compuestos de la presente invención.

La persona medianamente experta en la materia que estuviera interesada en reducir la producción de β -amiloide no habría utilizado una referencia completamente distante como es D2 que funcionan como a antagonistas de receptores P2X3.

Adicionalmente, el principal propósito de los compuestos del documento D2 es para el manejo del dolor. De acuerdo con el párrafo [0069], los compuestos "son útiles en la terapia, especialmente para aliviar varias condiciones de dolor tales como dolor crónico, dolor neuropático, dolor agudo, dolor causado por artritis reumatoide, migraña, dolor visceral etc". Esto no es extraño ya que los receptores P2X3 desde hace mucho se han asociado al manejo del dolor. La mencionada solicitud de patente también incluye una amplia lista de otras indicaciones también muy distantes. Estas incluyen "cáncer, esclerosis múltiple, enfermedad de Parkinson, corea de Huntington, enfermedad de Alzheimer, trastorno de ansiedad, trastorno gastrointestinal y trastornos cardiovasculares". De manera extraña, el

documento D2 también reclama tratar la diarrea y también alergias!!. En otras palabras, este documento hace la reclamación altamente implacable para tratar todo tipo de enfermedad que afecta al ser humano.

Por último, existe también un asunto estructural importante con los compuestos del documento D2. Hay un grupo carbonilo ($-C=O$) que se extiende desde el anillo de cinco miembros hasta el grupo de pirimidina. Este componente carbonilo no está presente en la estructura reivindicada del solicitante en el anillo de cinco miembros. Al omitir simplemente esta importante característica de los compuestos propios de la solicitante no debería considerarse de ninguna manera las enseñanzas del documento D2.

De conformidad con lo anterior, mi representada respetuosamente afirma que no es apropiada la combinación de los documentos D1 y D2, y por lo tanto, dichos documentos no pueden afectar de ninguna manera el nivel inventivo de la presente solicitud.

En consecuencia, la presente invención relaciona compuestos nuevos e inventivos para la reducción de producción de β -amiloide. El documento D1 no enseña ni revela el grupo amina importante unido al anillo pirimidina, y el combinar D1 con D2 con es correcto para el análisis de nivel inventivo de esta invención por varias razones entre ellas los compuestos del documento D2 funcionan como antagonistas de receptores P2X3 en particular para tratar el dolor y los compuestos de la solicitud en estudio se dirigen a la reducción de la producción de β -amiloide. Es decir, al ser documentos tan alejados en la finalidad de los compuestos una persona medianamente versada en la materia no se fijaría en las enseñanzas de D2 para buscar compuestos que redujeran la producción de β -amiloide. Además existe una diferencia estructural muy importante entre los compuestos de la solicitud en estudio y el documento D2, esto es el grupo carbonilo del documento D2 que se extiende desde el anillo de cinco miembros hasta el grupo de pirimidina. Este componente carbonilo no está presente en la estructura reivindicada por la presente invención en el anillo de cinco miembros. Por lo tanto, la diferencia estructural y la diferencia en la funcionalidad de los compuestos de la presente invención con el documento D2 deja claro que el documento D2 no es arte previo para afectar el nivel inventivo de la solicitud en estudio y tampoco lo es el documento D1 por las razones arriba citadas.

3. Solicitudes concedidas en otros países para esta misma invención.

En virtud de lo anterior, solicito que se acepten las razones expuestas en el presente documento y en consecuencia, se otorgue el privilegio de patente de invención para el invento que se tramita en este expediente.


ÁLVARO CORREA ORDÓÑEZ
C.C.No.79.143.366 de Usaquén

Anexos:

- Capítulo reivindicatorio modificado conformado por 8 reivindicaciones
- Copia de la carátula y reivindicaciones de la patente Estadounidense No. 8, 486, 952.

REIVINDICACIONES

1. Un compuesto de fórmula (I)




(I),

o una sal farmacéuticamente aceptable del mismo; en la que

A es un anillo heteroaromático de cinco miembros que contiene de dos a tres heteroátomos de nitrógeno, en el que dicho anillo heteroaromático está sustituido con un grupo halo;

B es fenilo, en el que el fenilo está sustituido con uno o dos sustituyentes seleccionados independientemente de alcoxi C₁₋₆, y halo;

D se selecciona de



"" indica el punto de unión del átomo de nitrógeno a la molécula parental;
 "" indica el punto de unión al resto 'E';

R^a se selecciona de hidrógeno;

R^b es -NR^xR^y, en el que R^x y R^y están independientemente seleccionados de hidrógeno, alcoxi C₁₋₄, alcoxi C₁₋₄-alquilo C₁₋₄, alcoxycarbonilo C₁₋₄, alquilo C₁₋₆, cicloalquilo C₃₋₇, (cicloalquilo C₃₋₇)alquilo C₁₋₄, hidroxialquilo C₁₋₄ y trideuterometilo, en los que la parte alquilo del (cicloalquilo C₃₋₇)alquilo C₁₋₄ puede estar sustituida con grupo alcoxi C₁₋₄; o, R^x y R^y, conjuntamente con el átomo de nitrógeno al que están unidos, forman un anillo monocíclico o bicíclico de cuatro a siete miembros que contiene un doble enlace y que contiene un heteroátomo adicional seleccionado de O, NR^z y S; en el que R^z se selecciona de hidrógeno, alquilo C₁₋₆ y alcoxycarbonilo C₁₋₄; y en el que el anillo está sustituido con uno o dos sustituyentes seleccionados independientemente de alcoxi C₁₋₆, alquilo C₁₋₆, halo, haloalquilo C₁₋₄, hidroxilo, -NR^fR^g, oxo, dioxolanilo espirocíclico; en el que R^f y R^g están independientemente


seleccionados a partir de hidrógeno, alcóxicarbonilo C₁₋₄ y alquilo C₁₋₆;

R^c es hidrógeno;

y

E es fenilo en el que el fenilo está sustituido con un halo.


2. Un compuesto de la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, en el que D se selecciona de



3. Un compuesto de la reivindicación 2, o una sal farmacéuticamente aceptable del mismo, en el que R^b es -NR^xR^y, en el que R^x y R^y se seleccionan independientemente de hidrógeno, alcoxi C₁₋₄alquilo C₁₋₄, alquilo C₁₋₆, cicloalquilo C₃₋₇, hidroxialquilo C₁₋₄ y trideuterometilo, en el que la parte alquilo del (cicloalquilo C₃₋₇)alquilo C₁₋₄ puede estar sustituida con un grupo alcoxi C₁₋₄.

4. Un compuesto de la reivindicación 2, o una sal farmacéuticamente aceptable del mismo, en el que R^b es -NR^xR^y, en el que R^x y R^y, conjuntamente con el átomo de nitrógeno al que están unidos, forman un anillo monocíclico o bicíclico de cuatro a siete miembros que contiene un heteroátomo adicional seleccionado de O y NR^z; en el que R^z se selecciona de alquilo C₁₋₆ y alcóxicarbonilo C₁₋₄; y en el que el anillo está sustituido con uno o dos sustituyentes independientemente seleccionados de alcoxi C₁₋₆, alquilo C₁₋₆, halo, haloalquilo C₁₋₄, hidroxilo, -NR^fR^g, oxo y dioxolanilo espirocíclico; en los que R^f y R^g están independientemente seleccionados de hidrógeno, alcóxicarbonilo C₁₋₄ y alquilo C₁₋₆.

5. Un compuesto de la reivindicación 1, o una sal farmacéuticamente aceptable del mismo, en el que D está seleccionado de.



6. Un compuesto de la reivindicación 5, o una sal farmacéuticamente aceptable del mismo, en el que R^b es -NR^xR^y, en el que R^x y R^y se seleccionan independientemente

de hidrógeno, alcoxi C₁₋₄alquilo C₁₋₄, alquilo C₁₋₆, cicloalquilo C₃₋₇, hidroxialquilo C₁₋₄ y trideuterometilo, en los que la parte alquilo del (cicloalquilo C₃₋₇)alquilo C₁₋₄ puede estar sustituida con un grupo alcoxi C₁₋₄.

7. Un compuesto de la reivindicación 5, o una sal farmacéuticamente aceptable del mismo, en el que R^b es -NR^xR^y, en el que R^x y R^y, conjuntamente con el átomo de nitrógeno al que están unidos, forman un anillo monocíclico o bicíclico de cuatro a siete miembros que contiene un heteroátomo adicional seleccionado de O y NR^z; en el que R^z se selecciona de alquilo C₁₋₆ y alcóxicarbonilo C₁₋₄; y en el que el anillo está sustituido con uno o dos sustituyentes independientemente seleccionados de alcoxi C₁₋₆, alquilo C₁₋₆, halo, haloalquilo C₁₋₄, hidroxilo, -NR^fR^g, oxo y dioxolanilo espirocíclico; en los que R^f y R^g están independientemente seleccionados de hidrógeno, alcóxicarbonilo C₁₋₄ y alquilo C₁₋₆.

8. Un compuesto seleccionado de

N2-(3-metoxi-4-(3-metil-1H-1,2,4-triazol-1-ilo)fenilo)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N2-(3-fluoro-4-(3-metil-1H-1,2,4-triazol-1-ilo)fenilo)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N2-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-N⁴-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

12
N²-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-N⁴-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴,N⁴-dimetil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(S)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴,N⁴-dimetil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(R)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴,N⁴-dimetil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-etil-N⁴-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(S)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-etil-N⁴-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(R)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-etil-N⁴-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

4-(azetidin-1-ilo)-N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

(S)-4-(azetidin-1-ilo)-N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

(R)-4-(azetidin-1-ilo)-N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(S)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(R)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-ciclopropil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-ciclobutil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-isopropil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(S)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(R)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-7-(4-fluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(2-fluoro-5-metoxi-4-(3-metil-1H-1,2,4-triazol-1-ilo)fenilo)-7-(4-fluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(6-(4-cloro-1H-imidazol-1-ilo)-5-metoxipiridin-3-ilo)-7-(4-fluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(3,3-difluoroazetidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

4-(3,3-difluoroazetidin-1-ilo)-N-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

4-(3,3-difluoroazetidin-1-ilo)-N-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

4-(3,3-difluoroazetidin-1-ilo)-N-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(3-cloro-1H-1,2,4-triazol-1-ilo)-3-metoxifenilo)-4-(3,3-difluoroazetidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(3-cloro-1H-1,2,4-triazol-1-ilo)-3-metoxifenilo)-4-(3,3-difluoroazetidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(3-cloro-1H-1,2,4-triazol-1-ilo)-3-metoxifenilo)-4-(3,3-difluoroazetidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

4-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-ilo)-N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

4-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-ilo)-N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

4-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-ilo)-N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-(2-metilpirrolidin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-(2-metilpirrolidin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-(2-metilpirrolidin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-(2-metilpirrolidin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-(2-metilpirrolidin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-(2-metilpirrolidin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-((2S,6R)-2,6-dimetilmorfolino)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-((2S,6R)-2,6-dimetilmorfolino)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-((2S,6R)-2,6-dimetilmorfolino)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

1-(2-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilamino)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-ilo)-4-metilpiperidin-4-ol;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(2-etilpirrolidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(2-etilpirrolidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(2-etilpirrolidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(2-etilpirrolidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(2-etilpirrolidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(2-etilpirrolidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

4-(4-amino-4-metilpiperidin-1-ilo)-N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N²-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-7-(4-fluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-7-(4-fluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-7-(4-fluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

1-(2-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilamino)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-ilo)-3-(trifluorometil)pirrolidin-3-ol;

1-(2-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilamino)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-ilo)-3-(trifluorometil)pirrolidin-3-ol;

1-(2-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilamino)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-ilo)-3-(trifluorometil)pirrolidin-3-ol;

1-(2-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilamino)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-ilo)-3-(trifluorometil)pirrolidin-3-ol;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(3-(dimetilamino)pirrolidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(3-(dimetilamino)pirrolidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(3-(dimetilamino)pirrolidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-(4-metilpiperazin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-(4-metilpiperazin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-(4-metilpiperazin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-(piperazin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-(3-(metilamino)pirrolidin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-(3-(metilamino)azetidin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(3-(dimetilamino)azetidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N²-(3-fluoro-4-(3-metil-1H-1,2,4-triazol-1-ilo)fenilo)-7-(4-fluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-((S)-3-fluoropirrolidin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-((S)-3-fluoropirrolidin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-((R)-3-fluoropirrolidin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-((R)-3-fluoropirrolidin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina);

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(4,4-difluoropiperidin-1-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(4-fluoro-5,6-dihidropiridin-1(2H)-ilo)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-(3-(trifluorometil)pirrolidin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-(3-etoxipropil)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

3-(2-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilamino)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-ilamino)propan-1-ol;

7-(4-fluorofenilo)-N²-(3-metoxi-4-(3-metil-1H-1,2,4-triazol-1-ilo)fenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-(1-ciclopropil-2-metoxietil)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-N⁴,N⁴-dimetil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(S)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-N⁴,N⁴-dimetil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(R)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-N⁴,N⁴-dimetil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-N⁴-trideuterometil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-N⁴-(1-metoxibutan-2-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N2-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N4-((R)-1-ciclopropiletil)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;
N2-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N4-((S)-1-ciclopropiletil)-7-(4-fluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-((S)-2-metilpirrolidin-1-ilo)-5,7-dihidrofuro[3,4-d]pirimidin-2-amina ;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-etil-7-(4-fluorofenilo)-5,7-dihidrofuro[3,4-d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-etil-7-(4-fluorofenilo)-5,7-dihidrofuro[3,4-d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-etil-7-(4-fluorofenilo)-5,7-dihidrofuro[3,4-d]pirimidina-2,4-diamina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-((S)-3-fluoropirrolidin-1-ilo)-5,7-dihidrofuro[3,4-d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-((S)-3-fluoropirrolidin-1-ilo)-5,7-dihidrofuro[3,4-d]pirimidin-2-amina;

N⁴-etil-N²-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-7-(4-fluorofenilo)-5,7-dihidrofuro[3,4-d]pirimidina-2,4-diamina;

N⁴-etil-N²-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-7-(4-fluorofenilo)-5,7-dihidrofuro[3,4-d]pirimidina-2,4-diamina;

N⁴-etil-N²-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-7-(4-fluorofenilo)-5,7-dihidrofuro[3,4-d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-N⁴-metil-5,7-dihidrofuro[3,4-d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-N⁴-metil-5,7-dihidrofuro[3,4-d]pirimidina-2,4-diamina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(3,3-difluoroazetidín-1-ilo)-7-(4-fluorofenilo)-5,7-dihidrofuro[3,4-d]pirimidin-2-amina;

N2-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N4-((R)-1-ciclopropiletil)-7-(4-fluorofenilo)-5,7-dihidrofuro[3,4-d]pirimidina-2,4-diamina;

N2-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-7-(4-fluorofenilo)-N4-metil-5,7-dihidrofuro[3,4-d]pirimidina-2,4-diamina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-fluorofenilo)-4-((R)-3-

fluoropirrolidin-1-ilo)-5,7-dihidrofuro[3,4-d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-((2S,6R)-2,6-dimetilmorfolino)-7-(4-fluorofenilo)-5,7-dihidrofuro[3,4-d]pirimidin-2-amina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-clorofenilo)-N⁴,N⁴-dimetil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-clorofenilo)-4-(3,3-difluoroazetidin-1-ilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-clorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(S)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-clorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(R)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-clorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(3,4-difluorofenilo)-N⁴,N⁴-dimetil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(S)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(3,4-difluorofenilo)-N⁴,N⁴-dimetil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(R)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(3,4-difluorofenilo)-N⁴,N⁴-dimetil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(3,4-difluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(S)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(3,4-difluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(R)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(3,4-difluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-metil-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(S)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-metil-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(R)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-metil-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-etil-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

- (S)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-etil-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;
- (R)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-etil-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;
- N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(3,3-difluoroazetidin-1-ilo)-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;
- (S)-N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(3,3-difluoroazetidin-1-ilo)-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;
- (R)-N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(3,3-difluoroazetidin-1-ilo)-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;
- N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴,N⁴-dimetil-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;
- (S)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴,N⁴-dimetil-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;
- (R)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴,N⁴-dimetil-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;
- 4-(azetidin-1-ilo)-N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;
- (S)-4-(azetidin-1-ilo)-N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;
- (R)-4-(azetidin-1-ilo)-N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(4-(trifluorometoxi)fenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;
- N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(3,5-difluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;
- N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-metil-7-(3,4,5-trifluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;
- (S)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-metil-7-(3,4,5-trifluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;
- (R)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-metil-7-(3,4,5-trifluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;
- N²-(3-fluoro-4-(5-metil-1H-1,2,4-triazol-1-ilo)fenilo)-N⁴-metil-7-(3,4,5-trifluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;
- N²-(6-(4-cloro-1H-imidazol-1-ilo)-5-metoxipiridin-3-ilo)-N⁴-metil-7-(3,4,5-trifluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(3-cloro-1H-1,2,4-triazol-1-ilo)-3-metoxifenilo)-N⁴-metil-7-(3,4,5-trifluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(3,3-difluoropirrolidin-1-ilo)-7-(3,4,5-trifluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

(S)-N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(3,3-difluoropirrolidin-1-ilo)-7-(3,4,5-trifluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

(R)-N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(3,3-difluoropirrolidin-1-ilo)-7-(3,4,5-trifluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-4-(3,3-difluoroazetidin-1-ilo)-7-(3,4,5-trifluorofenilo)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(2,4-difluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(S)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(2,4-difluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(R)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-7-(2,4-difluorofenilo)-N⁴-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-etil-7-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-etil-7-alil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-trideuterometil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(S)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-trideuterometil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

(R)-N²-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilo)-N⁴-trideuterometil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidina-2,4-diamina;

2-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilamino)-4-(dimetilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-7-ol;

(6S,7S)-2-(4-(4-cloro-1H-imidazol-1-ilo)-3-metoxifenilamino)-4-(dimetilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-6-ol;

N-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenil)-4-(3-cloroazetidin-1-il)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenil)-4-(3-fluoroazetidin-1-il)-7-fenil-6,7-

2A
dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenil)-4-(3-metoxiazetidin-1-il)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenil)-7-fenil-4-(5,8-dioxa-2-azaspiro[3,4]octan-2-il)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

1-(2-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-il)azetidin-3-ona;

1-(2-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenilamino)-7-(4-fluorofenil)-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-il)-3-metilazetidina-3-carbonitrilo;

N-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenil)-4-(3-etoxiazetidin-1-il)-7-(4-fluorofenil)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenil)-7-fenil-4-(5-oxa-2-azaspiro[3,4]octan-2-il)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

1-(2-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenilamino)-7-(4-fluorofenil)-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-il)-3-metilazetidin-3-ol;

N-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenil)-4-(3-fluoro-3-metilazetidin-1-il)-7-(4-fluorofenil)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

N-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenil)-7-(4-fluorofenil)-4-(3-metoxi-3-metilazetidin-1-il)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

7-(4-fluorofenil)-4-(3-metoxi-3-metilazetidin-1-il)-N-(3-metoxi-4-(3-metil-1H-1,2,4-triazol-1-il)fenil)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

7-(2,4-difluorofenil)-N2-(3-metoxi-4-(3-metil-1H-1,2,4-triazol-1-il)fenil)-N4-metil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

(S)-7-(2,4-difluorofenil)-N2-(3-metoxi-4-(3-metil-1H-1,2,4-triazol-1-il)fenil)-N4-metil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

(R)-7-(2,4-difluorofenil)-N2-(3-metoxi-4-(3-metil-1H-1,2,4-triazol-1-il)fenil)-N4-metil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

(±)-2-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenilamino)-4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-5-ona;

O-metil oxima de (E)-2-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenilamino)-4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-5-ona;

2-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenilamino)-4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-5-ol;

1-(2-metoxi-4-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-

ilamino)fenil)-1H-imidazol-4-carbonitrilo;

N-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenil)-7-fenil-4-(1,4-dioxa-7-azaspiro[4,4]nonan-7-il)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-amina;

1-(2-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-il)pirrolidin-3-ona;

N2-(4-(4-(difluorometil)-1H-imidazol-1-il)-3-metoxifenil)-7-(4-fluorofenil)-N4-metil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N2-(3-metoxi-4-(1-metil-1H-pirazol-4-il)fenil)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N-(2-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-il)-N-metilmetanosulfonamida;

N-(2-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-il)-N-metanosulfonamida;

N-(2-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-il)-N-metilacetamida;

N-(2-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-il)-N-acetamida;

N2-(4-(4-cloro-1H-imidazol-1-il)-3-metoxifenil)-N4-(5-isopropil-2-metilfenil)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

4-(4-(5-isopropil-2-metilfenilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)benzonitrilo;

N4-metil-N2-(2-metilpiridin-4-il)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N2-(3-metoxifenil)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N2-(4-fluorofenil)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N2-(3,5-difluorofenil)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N2-(4-cloro-3-metoxifenil)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N2-(4-bromo-2-metoxifenil)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N2-(4-fluoro-3-metoxifenil)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-

2,4-diamina;

N4-metil-7-fenil-N2-(pirimidin-5-il)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N4-metil-7-fenil-N2-(piridin-4-il)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;
4-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)benzonitrilo;

4-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)benzonitrilo;

4-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)benzonitrilo;

2-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)benzonitrilo;

4-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)-1-naftonitrilo;

5-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)picolinonitrilo;

2-(4-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)fenil)acetonitrilo;

2-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)-1H-benzo[d]imidazol-5-carbonitrilo;

3-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)benzonitrilo;

N2-(4-terc-butilfenil)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N4-metil-N2-(4-(metilsulfonil)fenil)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N4-metil-7-fenil-N2-(4-(trifluorometoxi)fenil)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

4-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)ftalonitrilo;

4-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)-2-(trifluorometil)benzonitrilo;

N4-metil-7-fenil-N2-(4-(trifluorometil)fenil)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

5-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)-2,3-dihidro-1H-inden-1-ona;

2-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)-1H-imidazol-4,5-dicarbonitrilo;

2-bromo-5-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)benzonitrilo;

N,N-dimetil-4-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)benzamida;

1-(4-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)fenil)ciclopentanocarbonitrilo;

N4-metil-7-fenil-N2-(1,2,3,4-tetrahidroisoquinolin-6-il)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

4-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)-2-(trifluorometoxi)benzonitrilo;

1-(4-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)fenil)ciclopropanocarbonitrilo;

1-(2-metoxi-4-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)fenilamino)ciclopropanocarbonitrilo;

N4-metil-N2-(2-metil-1H-indol-5-il)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N2-(benzofuran-5-il)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N2-(1H-indol-5-il)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N4-metil-N2-(2-metilbenzo[d]oxazol-6-il)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N2-(1H-benzo[d]imidazol-6-il)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N4-metil-N2-(1-metil-1H-indol-5-il)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N4-metil-N2-(2-metilbenzo[d]tiazol-6-il)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N2-(4-bromo-3-metoxifenil)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-

2,4-diamina;

1-(4-(4-(metilamino)-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2-ilamino)fenil)etanona;

N2-(4-ciclopropilfenil)-7-(4-fluorofenil)-N4-metil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N2-(4-etinilfenil)-7-(4-fluorofenil)-N4-metil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

7-(4-fluorofenil)-N4-metil-N2-(4-(prop-1-inil)fenil)-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N2-(3-metoxi-4-(2-metilpiridin-4-il)fenil)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina;

N2-(3-metoxi-4-(piridin-4-il)fenil)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina y

N2-(3-metoxi-4-(piridin-3-il)fenil)-N4-metil-7-fenil-6,7-dihidro-5H-ciclopenta[d]pirimidin-2,4-diamina; o una de sus sales farmacéuticamente aceptables.



US008486952B2

(12) **United States Patent**
Boy et al.

(10) **Patent No.:** **US 8,486,952 B2**
(45) **Date of Patent:** **Jul. 16, 2013**

(54) **COMPOUNDS FOR THE REDUCTION OF
β-AMYLOID PRODUCTION**
(75) **Inventors:** **Kenneth M. Boy**, Durham, CT (US);
Jason M. Guernon, Moodus, CT (US);
John E. Macor, Guilford, CT (US);
Richard E. Olson, Orange, CT (US);
Jianliang Shi, Madison, CT (US); **Lorin**
A. Thompson, III, Higganum, CT (US);
Yong-Jin Wu, Madison, CT (US); **Li**
Xu, Middletown, CT (US); **Yunhui**
Zhang, Glastonbury, CT (US); **Dmitry**
S. Zuev, Wallingford, CT (US)

(73) **Assignee:** **Bristol-Myers Squibb Company**,
Princeton, NJ (US)

(*) **Notice:** Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 157 days.

(21) **Appl. No.:** **12/845,045**

(22) **Filed:** **Jun. 28, 2010**

(65) **Prior Publication Data**
US 2011/0212937 A1 Sep. 1, 2011

Related U.S. Application Data
(60) Provisional application No. 61/324,201, filed on Apr.
14, 2010, provisional application No. 61/230,202,
filed on Jul. 31, 2009.

(51) **Int. Cl.**
A01N 43/54 (2006.01)
A01N 43/90 (2006.01)
A61K 31/517 (2006.01)
A61K 31/519 (2006.01)
A61K 31/52 (2006.01)
A61K 31/497 (2006.01)
A61K 31/00 (2006.01)
A61K 31/535 (2006.01)
C07D 239/70 (2006.01)
C07D 491/00 (2006.01)
C07D 495/00 (2006.01)
C07D 471/00 (2006.01)
C07D 413/00 (2006.01)

(52) **U.S. Cl.**
USPC **514/258.1**; 514/264.11; 514/252.16;
514/210.21; 514/260.1; 514/234.2; 514/230.5;
544/253; 544/278; 544/279; 544/117

(58) **Field of Classification Search**
USPC 514/258.1, 264.11, 252.16, 210.21,
514/260.1, 234.2, 230.5; 544/253, 278, 279,
544/117

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS
6,696,452 B2 2/2004 Davies et al.
7,115,739 B2 10/2006 Bebbington et al.
2010/0297128 A1 11/2010 Huang et al.

2010/0298359 A1 11/2010 Huang et al.
2010/0298372 A1 11/2010 Huang et al.
2010/0298381 A1 11/2010 Zhu et al.
2011/0009392 A1 1/2011 Zhu et al.
2011/0015190 A1 1/2011 Huang et al.

FOREIGN PATENT DOCUMENTS

WO WO 02/50065 6/2002
WO WO 2008/136756 11/2008
WO WO 2009/087127 7/2009
WO WO 2009/103652 8/2009
WO WO 2010/040661 4/2010
WO WO 2010/088408 8/2010
WO WO 2010/088414 8/2010
WO WO 2010/132015 11/2010
WO WO 2011/006903 1/2011

OTHER PUBLICATIONS

Anderson, D.H. et al., "Characterization of β amyloid assemblies in
drusen: the deposits associated with aging and age-related macular
degeneration," *Experimental Eye Research*, 78, pp. 243-256, 2004.
Barten, D.M. et al., "γ-Secretase Inhibitors for Alzheimer's Disease,"
Drugs R D, 7, 2, pp. 87-97, 2006.
Cleary, J.P. et al., "Natural oligomers of the amyloid-βprotein spe-
cifically disrupt cognitive function," *Nature Neuroscience*, vol. 8, No.
1, pp. 79-84, Jan. 2005.
Deramecourt V. et al., "Biochemical staging of Synucleinopathy and
Amyloid Deposition in Dementia with Lewy Bodies," *Journal of*
Neuropathology and Experimental Neurol., vol. 65, No. 3, pp. 278-
288, Mar. 2006.
Dess D.B. et al., "Readily Accessible 12-1-5¹ Oxidant for the Con-
version of Primary and Secondary Alcohols to Aldehydes and
Ketones," *Journal of Organic Chemistry*, 48, pp. 4155-4156, 1983.
Dirat O. et al., "Expeditious synthesis of novel NK₁ antagonists based
on a 1,2,4-trisubstituted cyclohexane," *Tetrahedron Letters*, 47, pp.
1295-1298, 2006.
Fox J.M. et al., Highly Active and Selective Catalysts for the Forma-
tion of α-Aryl Ketones, *Journal of the American Chemical Society*,
122, pp. 1360-1370, 2000.


(Continued)

Primary Examiner — Samira Jean-Louis

(74) *Attorney, Agent, or Firm* — John F. Lewis

(57) **ABSTRACT**

The present disclosure provides a series of compounds of the
formula (I)



which modulate β-amyloid peptide (β-AP) production and
are useful in the treatment of Alzheimer's Disease and
other conditions affected by β-amyloid peptide (β-AP)
production.

15 Claims, No Drawings

OTHER PUBLICATIONS


- Goldstein L.E. et al., "Cytosolic β -amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease," *The Lancet*, vol. 361, pp. 1258-1265, Apr. 12, 2003.
- Grundman M et al., "Mild Cognitive Impairment Can Be Distinguished from Alzheimer Disease and Normal Aging for Clinical Trials," *Archives of Neurology*, vol. 61, pp. 59-66, Jan. 2004.
- Hamilton R.L. et al., "Alzheimer disease pathology in amyotrophic lateral sclerosis," *Acta Neuropathology*, 107, pp. 515-522, 2004.
- Larsen J.S. et al., "Synthesis of annelated analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442) using 1,2-oxazine-2,4(3*H*)-diones as key intermediates," *J. Chem. Soc., Perkin Trans. 1*, pp. 3035-3038, 2000.
- Loane D.J. et al., "Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury," *Nature Medicine*, vol. 15, No. 4, pp. 377-379, Apr. 2009.
- "Consensus Recommendations for the Postmortem Diagnosis of Alzheimer's Disease," *Neurobiology of Aging*, vol. 18, No. S4, pp. S1-S2, 1997.
- Murphy, M.P. et al., "Inclusion-body myositis and Alzheimer disease: Two sides of the same coin, or different currencies altogether?" *Neurology*, 66, Suppl 1, pp. S65-S68, 2006.
- Nencka R. et al., "Discovery of 5-Substituted -6-chlorouracils as Efficient Inhibitors of Human Thymidine Phosphorylase," *Journal of Medicinal Chemistry*, 50, pp. 6016-6023, 2007.
- Neumann M. et al., "Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis," *Science*, vol. 314, pp. 130-133, Oct. 6, 2006.
- Tyle, "Iontophoretic Devices for Drug Delivery," *Pharmaceutical Research*, vol. 3, No. 6, pp. 318-326, 1986.
- Selkoe, "Alzheimer's Disease: Genes, Proteins, and Therapy," *Physiological Reviews*, vol. 81, No. 2, pp. 741-766, Apr. 2001.
- Thaer B.A. et al., "A Convenient Synthesis of 1-(4-Fluorophenyl)-2-(4-pyridyl)cyclopentene from Cyclopentanone," *Synthesis*, No. 2, pp. 225-228, 2008.
- Thal D.R. et al., "Two Types of Sporadic Cerebral Amyloid Angiopathy," *Journal of Neuropathology and Experimental Neurology*, vol. 61, No. 3, pp. 282-293, Mar. 2002.
- Walsh D.M. et al., "Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease," *Neuron*, vol. 44, pp. 181-193, Sep. 30, 2004.
- Watkins T.A. et al., "Distinct Stages of Myelination Regulated by γ -Secretase and Astrocytes in a Rapidly Myelinating CNS Coculture System," *Neuron*, 60, pp. 555-569, Nov. 26, 2008.
- Wolfe M.S. et al., "Intramembrane Proteolysis: Theme and Variations," *Science*, vol. 305, pp. 1119-1123, Aug. 20, 2004.
- Wolfe M.S., "Secretase Targets for Alzheimer's Disease, Identification and Therapeutic Potential," *Journal of Medicinal Chemistry*, vol. 44, No. 13, pp. 2039-2060, Jun. 21, 2001.
- Yokota O. et al., "NACP/ α -Synuclein, NAC, and β -amyloid pathology of familial Alzheimer's disease with the E184D presenilin-1 mutation: a clinicopathological study of two autopsy cases," *Acta Neuropathol*, 104, pp. 637-648, 2002.
- Yoshida T. et al., "The potential role of amyloid β in the pathogenesis of age-related macular degeneration," *The Journal of Clinical Investigation*, vol. 115, No. 10, pp. 2793-2800, Oct. 2005.

487

therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

What is claimed is:

1. A compound of formula (I)




or a pharmaceutically acceptable salt thereof, wherein

A is a five- or six-membered heteroaromatic ring containing from one to three heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said heteroaromatic ring is optionally substituted with one or two groups selected from halo, haloC₁₋₆alkyl, hydroxy, amino, C₁₋₆alkoxy, and C₁₋₆alkyl;


B is selected from phenyl and pyridinyl, wherein the phenyl and pyridinyl are optionally substituted with one or two substituents independently selected from C₁₋₆alkoxy, C₁₋₆alkyl, C₁₋₃alkylamino-C₁₋₆alkoxy, cyano, C₁₋₃dialkylamino-C₁₋₆alkoxy, halo, haloC₁₋₆alkoxy, haloC₁₋₆alkyl, hydroxy, methylamino, and amino;

D is selected from



488

-continued



" $\frac{1}{2}$ " denotes the point of attachment to the nitrogen atom of the parent molecule;

" $\frac{1}{2}$ " denotes the point of attachment to the 'E' moiety; R^a is selected from hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, and hydroxy;

R^b is —NR^xR^y, wherein R^x and R^y are independently selected from hydrogen, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₆alkyl, C₃₋₇cycloalkyl, (C₃₋₇cycloalkyl)C₁₋₄alkyl, hydroxyC₁₋₄alkyl, and tridenteromethyl, wherein the alkyl part of the (C₃₋₇cycloalkyl)C₁₋₄alkyl can be optionally substituted with a C₁₋₄alkoxy group; or, R^x and R^y, together with the nitrogen atom to which they are attached, form a four- to seven-membered monocyclic or bicyclic ring optionally containing one double bond and optionally containing one additional heteroatom selected from O, NR^z, and S; wherein R^z is selected from hydrogen, C₁₋₆alkyl, and C₁₋₄alkoxycarbonyl; and wherein the ring is optionally substituted with one or two substituents indepen-

489

dently selected from C₁₋₆alkoxy, C₁₋₆alkyl, halo, haloC₁₋₄alkyl, hydroxy, —NR^rR^s, oxo, spirocyclic dioxolanyl; wherein R^r and R^s are independently selected from hydrogen, C₁₋₄alkoxycarbonyl, and C₁₋₆alkyl;

R^c is selected from hydrogen, C₁₋₄alkylsulfonyl, C₁₋₄alkylsulfonylamido, amino, C₁₋₆alkylamino, C₁₋₆dialkylamino, C₃₋₇cycloalkylamino, hydroxy, and C₁₋₄alkoxy;

R^d is selected from hydrogen, C₁₋₆alkyl, C₁₋₄alkoxyC₁₋₄alkylcarbonyl,


C₁₋₆alkoxycarbonyl, C₁₋₆alkylcarbonyl, C₁₋₆alkylsulfonyl, C₃₋₇cycloalkylsulfonyl, C₃₋₇cycloalkylcarbonyl, C₁₋₆dialkylaminoC₁₋₄alkylcarbonyl, and haloC₁₋₄alkyl, wherein the alkyl part of the alkoxycarbonyl, the alkylcarbonyl, and the alkylsulfonyl are optionally substituted with one substituent selected from C₁₋₄dialkylamino, and C₁₋₄alkoxy; and

E is selected from C₄₋₆cycloalkyl, (C₄₋₇cycloalkyl)C₁₋₄alkyl, benzyl, phenyl, and a five- to six-membered heteroaromatic ring containing one or two nitrogen atoms, wherein the phenyl, the phenyl part of the benzyl, and the heteroaromatic ring are each optionally substituted with one, two, or three substituents independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, cyano, halo, haloC₁₋₆alkoxy, and haloC₁₋₆alkyl.

2. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is a five-membered heteroaromatic ring containing from one to three nitrogen atoms; wherein said heteroaromatic ring is optionally substituted with one group selected from halo and C₁₋₆alkyl.

3. A compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein B is selected from phenyl and pyridinyl, wherein the phenyl and pyridinyl are optionally substituted with one or two substituents independently selected from C₁₋₆alkoxy and halo.

4. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein D is selected from




5. A compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R^b is —NR^xR^y, wherein R^x and R^y are independently selected from hydrogen, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₆alkyl, C₃₋₇cycloalkyl, hydroxyC₁₋₄alkyl, and tri-deuteriomethyl, wherein the alkyl part of the (C₃₋₇cycloalkyl) C₁₋₄alkyl can be optionally substituted with a C₁₋₄alkoxy group.

6. A compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R^b is —NR^xR^y, wherein R^x and R^y, together with the nitrogen atom to which they are attached, form a four- to seven-membered monocyclic or bicyclic ring optionally containing one additional heteroatom selected from O and NR^z; wherein R^z is selected from C₁₋₆alkyl, and

490

C₁₋₄alkoxycarbonyl; and wherein the ring is optionally substituted with one or two substituents independently selected from C₁₋₆alkoxy, C₁₋₆alkyl, halo, haloC₁₋₄alkyl, hydroxy, —NR^rR^s, oxo, and spirocyclic dioxolanyl; wherein R^r and R^s are independently selected from hydrogen, C₁₋₄alkoxycarbonyl, and C₁₋₆alkyl.

7. A compound of formula (I)




or a pharmaceutically acceptable salt thereof, wherein

A is a five-membered heteroaromatic ring containing from one to three nitrogen atoms; wherein said heteroaromatic ring is optionally substituted with one group selected from halo and C₁₋₆alkyl;


B is selected from phenyl and pyridinyl, wherein the phenyl and pyridinyl are optionally substituted with one or two substituents independently selected from

C₁₋₆alkoxy and halo;

D is selected from



491



“ $\sim$ ” denotes the point of attachment to the nitrogen atom of the parent molecule;

“ $\sim$ ” denotes the point of attachment to the ‘E’ moiety; R^a is selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, and hydroxy;

R^b is $-NR^xR^y$, wherein R^x and R^y are independently selected from hydrogen, C_{1-4} alkoxy, C_{1-4} alkoxy C_{1-4} alkyl, C_{1-4} alkoxycarbonyl, C_{1-6} alkyl, C_{3-7} cycloalkyl, $(C_{3-7}$ cycloalkyl) C_{1-4} alkyl, hydroxy C_{1-4} alkyl, and trideuteromethyl, wherein the alkyl part of the $(C_{3-7}$ cycloalkyl) C_{1-4} alkyl can be optionally substituted with a C_{1-4} alkoxy group; or, R^x and R^y , together with the nitrogen atom to which they are attached, form a four- to seven-membered monocyclic or bicyclic ring optionally containing one double bond and optionally containing one additional heteroatom selected from O, NR^z , and S; wherein R^z is selected from hydrogen, C_{1-6} alkyl, and C_{1-4} alkoxycarbonyl; and wherein the ring is optionally substituted with one or two substituents independently selected from C_{1-6} alkoxy, C_{1-6} alkyl, halo, halo C_{1-4} alkyl, hydroxy, $-NR^fR^g$, oxo, spirocyclic dioxolanyl; wherein R^f and R^g are independently selected from hydrogen, C_{1-4} alkoxycarbonyl, and C_{1-6} alkyl;

R^c is selected from hydrogen, C_{1-4} alkylsulfonyl, C_{1-4} alkylsulfonylamido, amino, C_{1-6} alkylamino, C_{1-6} dialkylamino, C_{3-7} cycloalkylamino, hydroxy, and

492


C_{1-4} alkoxy;

R^d is selected from hydrogen, C_{1-6} alkyl, C_{1-4} alkoxy C_{1-4} alkylcarbonyl,

C_{1-6} alkoxycarbonyl, C_{1-6} alkylcarbonyl, C_{1-6} alkylsulfonyl, C_{3-7} cycloalkylsulfonyl, C_{3-7} cycloalkylcarbonyl, C_{1-6} dialkylamino C_{1-4} alkylcarbonyl, and halo C_{1-4} alkyl, wherein the alkyl part of the alkoxycarbonyl, the alkylcarbonyl, and the alkylsulfonyl are optionally substituted with one substituent selected from C_{1-4} dialkylamino, and C_{1-4} alkoxy; and

E is phenyl, wherein the phenyl is optionally substituted with one, two, or three substituents independently selected from C_{1-6} alkyl, C_{1-6} alkoxy, cyano, halo, halo C_{1-6} alkoxy, and halo C_{1-6} alkyl.


8. A compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein D is selected from




9. A compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R^b is $-NR^xR^y$, wherein R^x and R^y are independently selected from hydrogen, C_{1-4} alkoxy C_{1-4} alkyl, C_{1-6} alkyl, C_{3-7} cycloalkyl, hydroxy C_{1-4} alkyl, and trideuteromethyl, wherein the alkyl part of the $(C_{3-7}$ cycloalkyl) C_{1-4} alkyl can be optionally substituted with a C_{1-4} alkoxy group.

10. A compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R^b is $-NR^xR^y$, wherein R^x and R^y are independently selected from hydrogen, C_{1-4} alkoxy C_{1-4} alkyl, C_{1-6} alkyl, C_{3-7} cycloalkyl, hydroxy C_{1-4} alkyl, and trideuteromethyl, wherein the alkyl part of the $(C_{3-7}$ cycloalkyl) C_{1-4} alkyl can be optionally substituted with a C_{1-4} alkoxy group.

11. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein D is selected from



493



12. A compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R^b is $—NR^xR^y$, wherein R^x and R^y are independently selected from hydrogen, C_{1-4} alkoxy C_{1-4} alkyl, C_{1-6} alkyl, C_{3-7} cycloalkyl, hydroxy C_{1-4} alkyl, and tri-deuteriomethyl, wherein the alkyl part of the (C_{3-7} cycloalkyl) C_{1-4} alkyl can be optionally substituted with a C_{1-4} alkoxy group.

13. A compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R^b is $—NR^xR^y$, wherein R^x and R^y , together with the nitrogen atom to which they are attached, form a four- to seven-membered monocyclic or bicyclic ring optionally containing one additional heteroatom selected from O and NR^z; wherein R^z is selected from C_{1-6} alkyl, and C_{1-4} alkoxycarbonyl; and wherein the ring is optionally substituted with one or two substituents independently selected from C_{1-6} alkoxy, C_{1-6} alkyl, halo, halo C_{1-4} alkyl, hydroxy, $—NR^tR^s$, oxo, and spirocycle dioxolanyl; wherein R^t and R^s are independently selected from hydrogen, C_{1-4} alkoxycarbonyl, and C_{1-6} alkyl.

14. A compound selected from
 N2-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 N2-(3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 N2-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 N²-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N⁴-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 N²-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N⁴-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴,N⁴-dimethyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 (S)—N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴,N⁴-dimethyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 (R)—N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴,N⁴-dimethyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-ethyl-N⁴-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 (S)—N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-ethyl-N⁴-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 (R)—N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-ethyl-N⁴-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 4-(Azetidin-1-yl)-N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;

494

(S)-4-(Azetidin-1-yl)-N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
 (R)-4-(Azetidin-1-yl)-N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
 N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 (S)—N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 (R)—N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-cyclopropyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-cyclobutyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-isopropyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-N⁴-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 (S)—N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-N⁴-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 (R)—N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-N⁴-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 N²-(3-Fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N⁴-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 N²-(2-Fluoro-5-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N⁴-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 N²-(6-(4-chloro-1H-imidazol-1-yl)-5-methoxypyridin-3-yl)-7-(4-fluorophenyl)-N⁴-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
 N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(3,3-difluoroazetidin-1-yl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
 4-(3,3-difluoroazetidin-1-yl)-N-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
 4-(3,3-difluoroazetidin-1-yl)-N-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
 N-(4-(3-chloro-1H-1,2,4-triazol-1-yl)-3-methoxyphenyl)-4-(3,3-difluoroazetidin-1-yl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
 N-(4-(3-chloro-1H-1,2,4-triazol-1-yl)-3-methoxyphenyl)-4-(3,3-difluoroazetidin-1-yl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
 4-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;

496

4-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;		N ² -(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N ⁴ -methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
4-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;	5	1-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-(trifluoromethyl)pyrrolidin-3-ol;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-4-(2-methylpyrrolidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;	10	1-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-(trifluoromethyl)pyrrolidin-3-ol;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-4-(2-methylpyrrolidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;	15	1-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-(trifluoromethyl)pyrrolidin-3-ol;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-4-(2-methylpyrrolidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;	20	N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(3-(dimethylamino)pyrrolidin-1-yl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-4-(2-methylpyrrolidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;	25	N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(3-(dimethylamino)pyrrolidin-1-yl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-((2S,6R)-2,6-dimethylmorpholino)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;	30	N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-4-(4-methylpiperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-((2S,6R)-2,6-dimethylmorpholino)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;	35	N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-4-(4-methylpiperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-((2S,6R)-2,6-dimethylmorpholino)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;	40	N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-4-(3-(methylamino)pyrrolidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
1-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-4-methylpiperidin-4-ol;	45	N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-4-(3-(methylamino)azetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(2-ethylpyrrolidin-1-yl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;	50	N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(3-(dimethylamino)azetidin-1-yl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(2-ethylpyrrolidin-1-yl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;	55	N ² -(3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N ⁴ -methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(2-ethylpyrrolidin-1-yl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;	60	N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-4-((S)-3-fluoropyrrolidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
4-(4-amino-4-methylpiperidin-1-yl)-N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;	65	N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-4-((R)-3-fluoropyrrolidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
N ² -(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N ⁴ -methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;		N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(4-difluoropiperidin-1-yl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
N ² -(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N ⁴ -methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;		

500

69

N⁴-ethyl-N²-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-5,7-dihydrofuro[3,4-d]pyrimidine-2,4-diamine;
N⁴-ethyl-N²-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-5,7-dihydrofuro[3,4-d]pyrimidine-2,4-diamine;
N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-N⁴-methyl-5,7-dihydrofuro[3,4-d]pyrimidine-2,4-diamine;
N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-N⁴-methyl-5,7-dihydrofuro[3,4-d]pyrimidine-2,4-diamine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(3,3-difluoroazetidin-1-yl)-7-(4-fluorophenyl)-5,7-dihydrofuro[3,4-d]pyrimidin-2-amine;
N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-(R)-1-cyclopropylethyl)-7-(4-fluorophenyl)-5,7-dihydrofuro[3,4-d]pyrimidine-2,4-diamine;
N²-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7-(4-fluorophenyl)-N⁴-methyl-5,7-dihydrofuro[3,4-d]pyrimidine-2,4-diamine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-4-(R)-3-fluoropyrrolidin-1-yl)-5,7-dihydrofuro[3,4-d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-((2S,6R)-2,6-dimethylmorpholino)-7-(4-fluorophenyl)-5,7-dihydrofuro[3,4-d]pyrimidin-2-amine;
N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-methyl-8-phenyl-6,8-dihydro-5H-pyrano[3,4-d]pyrimidine-2,4-diamine;
N²-(3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N⁴-methyl-8-phenyl-6,8-dihydro-5H-pyrano[3,4-d]pyrimidine-2,4-diamine;
N²-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N⁴-methyl-8-phenyl-6,8-dihydro-5H-pyrano[3,4-d]pyrimidine-2,4-diamine;
N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-ethyl-8-(4-fluorophenyl)-6,8-dihydro-5H-pyrano[3,4-d]pyrimidine-2,4-diamine;
N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-ethyl-8-(4-fluorophenyl)-N⁴-methyl-6,8-dihydro-5H-pyrano[3,4-d]pyrimidine-2,4-diamine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-8-(4-fluorophenyl)-4-(R)-3-fluoropyrrolidin-1-yl)-6,8-dihydro-5H-pyrano[3,4-d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-8-(4-fluorophenyl)-4-(S)-3-fluoropyrrolidin-1-yl)-6,8-dihydro-5H-pyrano[3,4-d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-8-(4-fluorophenyl)-4-(S)-3-fluoropyrrolidin-1-yl)-6,8-dihydro-5H-pyrano[3,4-d]pyrimidin-2-amine;
N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-chlorophenyl)-N⁴-dimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-chlorophenyl)-4-(3,3-difluoroazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-chlorophenyl)-N⁴-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
(S)—N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-chlorophenyl)-N⁴-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;

503

8-(3,4-difluorophenyl)-N4-ethyl-N2-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine-2,4-diamine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-((R)-1-cyclopropylethyl)-8-(4-(trifluoromethyl)phenyl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine-2,4-diamine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-(trifluoromethyl)phenyl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine-2,4-diamine;
N4-ethyl-N2-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-8-(4-(trifluoromethyl)phenyl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine-2,4-diamine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-methyl-8-(4-(trifluoromethyl)phenyl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine-2,4-diamine;
4-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(ethylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-8-yl)benzonitrile;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-methyl-8-(4-(trifluoromethoxy)phenyl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine-2,4-diamine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-((R)-3-fluoropyrrolidin-1-yl)-8-(4-(trifluoromethoxy)phenyl)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-amine;
N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-ethyl-N⁴-methyl-8-phenyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
(S)—N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-ethyl-N⁴-methyl-8-phenyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
(R)—N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-ethyl-N⁴-methyl-8-phenyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-8-phenyl-5,6,7,8-tetrahydroquinazolin-2-amine;
N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-ethyl-8-(4-fluorophenyl)-N⁴-methyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-8-(4-fluorophenyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
(S)—N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-8-(4-fluorophenyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
(R)—N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-8-(4-fluorophenyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-8-(4-fluorophenyl)-5,6,7,8-tetrahydroquinazolin-2-amine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-methyl-6-(methylsulfonyl)-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-6-(cyclopropylsulfonyl)-N4-methyl-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
Methyl 2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(ethylamino)-8-phenyl-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate;
(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(ethylamino)-8-phenyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)(cyclopropyl)methanone;
1-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(ethylamino)-8-phenyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-2-methoxyethanone;

504

N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-ethyl-6-(methylsulfonyl)-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
1-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(ethylamino)-8-phenyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-2-(dimethylamino)ethanone;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-6-(cyclopropylsulfonyl)-N4-ethyl-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
1-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(ethylamino)-8-phenyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-ylethanone;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-ethyl-6-(ethylsulfonyl)-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N4-ethyl-N2-(3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-6-(methylsulfonyl)-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N4-ethyl-N2-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-6-(methylsulfonyl)-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
6-(cyclopropylsulfonyl)-N2-(3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4-methyl-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
6-(cyclopropylsulfonyl)-N2-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4-methyl-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
cyclopropyl(4-(ethylamino)-2-(3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenylamino)-8-phenyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)methanone;
cyclopropyl(4-(ethylamino)-2-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenylamino)-8-phenyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)methanone;
N4-ethyl-N2-(3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-8-phenyl-6-(2,2,2-trifluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N4-ethyl-N2-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-8-phenyl-6-(2,2,2-trifluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4,N4-dimethyl-6-(methylsulfonyl)-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4,6-dimethyl-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N2-(3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4,6-dimethyl-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N2-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4,6-dimethyl-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-ethyl-6-methyl-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N4-ethyl-N2-(3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-6-methyl-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N4-ethyl-N2-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-6-methyl-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-8-(4-fluorophenyl)-N4-methyl-6-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorophenyl)-6-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;

N4-ethyl-N2-(3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-8-(4-fluorophenyl)-6-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N4-ethyl-N2-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-6-(methylsulfonyl)-8-(4-fluorophenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4,6-diethyl-8-(4-fluorophenyl)-N4-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(3,3-difluoroazetidin-1-yl)-8-(4-fluorophenyl)-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(3,3-difluoroazetidin-1-yl)-8-(4-fluorophenyl)-6-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-amine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorophenyl)-N4-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(3,3-difluoroazetidin-1-yl)-8-(4-fluorophenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-amine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-8-(4-fluorophenyl)-N4,6-dimethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorophenyl)-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorophenyl)-N4,6-dimethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorophenyl)-N4-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2,4-diamine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-8-(4-fluorophenyl)-4-((S)-3-fluoropyrrolidin-1-yl)-7-(4-methoxybenzyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-amine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorophenyl)-7-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2,4-diamine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4,7-diethyl-8-(4-fluorophenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2,4-diamine;
methyl 2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(ethylamino)-8-(4-fluorophenyl)-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate;
1-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(ethylamino)-8-(4-fluorophenyl)-5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)ethanone;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorophenyl)-N4-methyl-7-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2,4-diamine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-8-(4-fluorophenyl)-4-((R)-3-fluoropyrrolidin-1-yl)-7-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-8-(4-fluorophenyl)-4-((R)-3-fluoropyrrolidin-1-yl)-7-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-amine;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-ethyl-8-(4-fluorophenyl)-7-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2,4-diamine;

N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-trideuteromethyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
(S)-N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-trideuteromethyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
(R)-N²-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N⁴-trideuteromethyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(methylamino)-8-phenyl-7,8-dihydroquinazolin-8-ol;
2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(methylamino)-8-phenyl-5,6,7,8-tetrahydroquinazolin-8-ol;
2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(dimethylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-7-ol; 7S)-2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(dimethylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-6-ol;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(3-chloroazetidin-1-yl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(3-fluoroazetidin-1-yl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(3-methoxyazetidin-1-yl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-phenyl-4-(5,8-dioxo-2-azaspiro[3.4]octan-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
1-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)azetidin-3-one;
1-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylazetidine-3-carbonitrile;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(3-ethoxyazetidin-1-yl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-phenyl-4-(5-oxa-2-azaspiro[3.4]octan-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
1-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-3-methylazetidin-3-ol;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-4-(3-fluoro-3-methylazetidin-1-yl)-7-(4-fluorophenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-4-(3-methoxy-3-methylazetidin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
7-(4-fluorophenyl)-4-(3-methoxy-3-methylazetidin-1-yl)-N-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
7-(2,4-difluorophenyl)-N2-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
(S)-7-(2,4-difluorophenyl)-N2-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;

(R)-7-(2,4-difluorophenyl)-N2-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
6-(2,2-difluoroethyl)-N4-ethyl-N2-(3-fluoro-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
6-(2,2-difluoroethyl)-N4-ethyl-N2-(3-fluoro-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N4-ethyl-N2-(3-methoxy-4-(4-chloro-1H-13-imidazol-1-yl)phenyl)-8-phenyl-6-(2,2,2-trifluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
N4-ethyl-N2-(3-methoxy-4-(4-chloro-1H-13-imidazol-1-yl)phenyl)-8-phenyl-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
8-(4-fluorophenyl)-N2-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4,6-dimethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
8-(4-fluorophenyl)-N2-(3-methoxy-4-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4,6-dimethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine;
(±)-2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5-one;
(E)-2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5-one O-methyl oxime; 2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5-ol;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-methyl-8-phenyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
1-(2-methoxy-4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)phenyl)-1H-imidazole-4-carbonitrile;
N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-7-phenyl-4-(1,4-dioxo-7-azaspiro[4.4]nonan-7-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-amine;
1-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)pyrrolidin-3-one;
4-(8-(4-fluorophenyl)-4-(methylamino)-6-(methylsulfonyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-ylamino)benzonitrile;
N2-(4-(4-(difluoromethyl)-1H-imidazol-1-yl)-3-methoxyphenyl)-7-(4-fluorophenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N2-(3-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-N-methylmethanesulfonamide;
N-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-N-methanesulfonamide;
N-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-N-methylacetamide;
N-(2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-N-acetamide;
N2-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)-N4-(5-isopropyl-2-methylphenyl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;

4-(4-(5-isopropyl-2-methylphenylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)benzonitrile;
N4-methyl-N2-(2-methylpyridin-4-yl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N2-(3-methoxyphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N2-(4-fluorophenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N2-(3,5-difluorophenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N2-(4-chloro-3-methoxyphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N2-(4-bromo-2-methoxyphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N2-(4-fluoro-3-methoxyphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N4-methyl-7-phenyl-N2-(pyrimidin-5-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N4-methyl-7-phenyl-N2-(pyridin-4-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)benzonitrile;
4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)benzonitrile;
4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)benzonitrile;
2-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)benzonitrile;
4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)-1-naphthonitrile;
5-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)picolinonitrile;
2-(4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)phenyl)acetoneitrile;
2-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)-1H-benzo[d]imidazole-5-carbonitrile;
3-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)benzonitrile;
N2-(4-tert-butylphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N4-methyl-N2-(4-(methylsulfonyl)phenyl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N4-methyl-7-phenyl-N2-(4-(trifluoromethoxy)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)phthalonitrile;
4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)-2-(trifluoromethyl)benzonitrile;
N4-methyl-7-phenyl-N2-(4-(trifluoromethyl)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
5-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)-2,3-dihydro-1H-inden-1-one;
2-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)-1H-imidazole-4,5-dicarbonitrile;
2-bromo-5-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)benzonitrile;
N,N-dimethyl-4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)benzamide;
1-(4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)phenyl)cyclopentanecarbonitrile;

509

N4-methyl-7-phenyl-N2-(1,2,3,4-tetrahydroisoquinolin-6-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)-2-(trifluoromethoxy) benzonitrile;
1-(4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)phenyl)cyclopropanecarbonitrile;
1-(2-methoxy-4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)phenylamino) cyclopropanecarbonitrile;
N4-methyl-N2-(2-methyl-1H-indol-5-yl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N2-(benzofuran-5-yl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N2-(1H-indol-5-yl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N4-methyl-N2-(2-methylbenzo[d]oxazol-6-yl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N2-(1H-benzo[d]imidazol-6-yl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N4-methyl-N2-(1-methyl-1H-indol-5-yl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N4-methyl-N2-(2-methylbenzo[d]thiazol-6-yl)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N2-(4-bromo-3-methoxyphenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;

510

1-(4-(4-(methylamino)-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-ylamino)phenyl)ethanone;
N2-(4-cyclopropylphenyl)-7-(4-fluorophenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N2-(4-ethynylphenyl)-7-(4-fluorophenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
7-(4-fluorophenyl)-N4-methyl-N2-(4-(prop-1-ynyl)phenyl)-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N2-(3-methoxy-4-(2-methylpyridin-4-yl)phenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine;
N2-(3-methoxy-4-(pyridin-4-yl)phenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine, and
N2-(3-methoxy-4-(pyridin-3-yl)phenyl)-N4-methyl-7-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine; or a pharmaceutically acceptable salt thereof.
15. A pharmaceutical composition for treating disorders responsive to reduction of β -amyloid peptide production comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier or diluent.

* * * * *